Homologous recombination deficiency (HRD) testing
for ovarian cancer

MyChoice® is a genomic test that guides PARP inhibitor treatment decisions for clinicians and
their patients with ovarian cancer

HRD testing has life-changing consequences for every woman with ovarian cancer, and MyChoice® is here to guide treatment decisions for each one.

MyChoice® examines ovarian cancer tumors by combining BRCA1 & 2 mutation analysis with a Genomic Instability Score, for comprehensive and accurate HRD results.1-4 MyChoice® identifies the right patients for PARP inhibitor treatment in time, and is the most validated HRD test in ovarian cancer.1,5-8

Young female scientist working on a digital tablet and examining a test tube sample while sitting at a table in a lab

Accurate results

MyChoice® accurately identifies more HRD+ patients than tests that measure BRCA1 & 2 status or loss of heterozygosity alone,1-4 ensuring clinicians have the most accurate information to make informed treatment decisions.

Shot of a senior woman using a digital tablet with a nurse on the sofa at home

Timely insights

Local testing with MyChoice® allows easy ordering and fast results, supporting clinicians to identify eligible patients for PARPi treatment in time.

Getty

Confident decisions

MyChoice® is a trusted partner, as the only HRD test with FDA approval,9 CE certification, recommendation in major international treatment guidelines10-12 and the most prospective phase III study data.1,5-8

Learn more about MyChoice®

I’m a clinician

I’m a patient

References

  1. Ray-Coquard, Isabelle, et al. “Olaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.” New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2416–2428.
  2. Timms, Kirsten M, et al. “Comparison of Genomic Instability Test Scores Used for Predicting PARP Activity in Ovarian Cancer.” Journal of Clinical Oncology, vol. 38, no. 15_suppl, 2020, pp. 1586–1586.
  3. Watkins, Johnathan A et al. “Genomic Scars As Biomarkers Of Homologous Recombination Deficiency And Drug Response In Breast And Ovarian Cancers”. Breast Cancer Research, vol 16, no. 3, 2014.
  4. The Cancer Genome Atlas Research Network. Nature 2011.
  5. Ray-Coquard, Isabelle, et al. “Olaparib Plus Bevacizuamb First-Line Maintenance in Ovarian Cancer: Final Overall Survival Results from the Paola-1/ENGOT-OV25 Trial.” Annals of Oncology, vol. 34, no. 8, 2023, pp. 681–692.
  6. González-Martín, Antonio, et al. “Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.” New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2391–2402.
  7. González-Martín, Antonio, et al. “Progression-Free Survival and Safety at 3.5 Years of Follow-up: Results from the Randomised Phase 3 Prima/Engot-OV26/GOG-3012 Trial of Niraparib Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer.” European Journal of Cancer, vol. 189, 2023, p. 112908.
  8. Coleman, Robert L., et al. “Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.” New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2403–2415.
  9. Cristescu, Razvan et al. “428 Genomic Instability Metric Concordance Between Oncoscan™, Cytosnp And An Fda-Approved HRD Test”. Translational Research, 2020.
  10. Tew, William P., et al. “Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.” Journal of Clinical Oncology, vol. 40, no. 33, 2022, pp. 3878–3881.
  11. Miller, Rowan E. et al. “ESMO Recommendations On Predictive Biomarker Testing For Homologous Recombination Deficiency And PARP Inhibitor Benefit In Ovarian Cancer”. Annals Of Oncology, vol 31, no. 12, 2020, pp. 1606-1622.
  12. National Comprehensive Cancer Network. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. Version 1.2023.

Locations

United States
Europe
Japan